UCL President and Provost, Professor Michael Arthur, visited the Division’s
Stanmore campus earlier this month, to meet staff and students from the
Institute of Orthopaedics and Musculoskeletal Science (IOMS) and the Royal
National Orthopaedic Hospital (RNOH).
Having recently collaborated with the Science Museum in February this year where she hosted a Nanotechnology workshop at the Science Museum’s Lates event, Melissa Bovis, Research Associate, teamed up with the Museum for a second time this month as part of their Building Bridges scheme. More...
40,000 men are diagnosed with prostate cancer every year in the UK. There is
much uncertainty about which treatments might be best for these men, so Level I
evidence is often required. Traditionally, Level I evidence comprises a
head-to-head randomised controlled trial (RCT) of a new intervention versus
placebo in which neither the patient nor the doctor knows who is taking what
(‘double-blind’). The treatment allocation is based on chance and the blinding
prevents biases. In surgery, this design is not always ethical or practical.
This means that both doctor and patient have to be made aware of the treatment
received in surgical trials. This causes problems. First, surgeons and patients
often have strong - but sometimes misplaced - ideas of what works, so RCTs are
difficult to recruit to. Second, this often means patients have to seek out
trials, leading to a select group of motivated, commonly more educated and
affluent patients participating in trials. Third, patients who take part in a
trial may not approve of the treatment they have been allocated by chance and
withdraw. These factors have led to the failure of many surgical trials to
accrue. This has been particularly highlighted in localised prostate cancer
RCTs. In fact, 11 RCTs evaluating different interventions in localised prostate
in the last decade have failed to recruit.
The Division is delighted
to announce that it has been awarded an Athena Swan Bronze Award for its
efforts in supporting and empowering women within the Division.